Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,256 Mln
P/E Ratio
--
P/B Ratio
3.89
Industry P/E
--
Debt to Equity
0.24
ROE
-0.95 %
ROCE
-68.42 %
Div. Yield
0 %
Book Value
1.88
EPS
-1.15
CFO
$-514.46 Mln
EBITDA
$-610.83 Mln
Net Profit
$-638.71 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ocular Therapeutix (OCUL)
| -1.70 | 10.75 | 6.27 | 76.92 | 30.47 | 7.64 | -10.02 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Ocular Therapeutix (OCUL)
| 90.47 | 58.72 | -59.68 | -66.33 | 424.05 | -0.75 | -10.51 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.03 | 6,904.81 | -- | 38.11 | |
| 73.24 | 7,574.08 | 58.3 | 23.56 | |
| 60.54 | 11,448.88 | 394.4 | 0.76 | |
| 8.36 | 9,704.70 | -- | -3.24 |
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The... company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Address: 15 Crosby Drive, Bedford, MA, United States, 01730 Read more
President, CEO & Director
Mr. Antony Mattessich
President, CEO & Director
Mr. Antony Mattessich
Headquarters
Bedford, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ocular Therapeutix Inc (OCUL) stood at $ 458 Mln as on 31-Dec-24
The share price of Ocular Therapeutix Inc (OCUL) is $8.40 (NASDAQ) as of 29-Apr-2025 12:43 EDT. Ocular Therapeutix Inc (OCUL) has given a return of 30.47% in the last 3 years.
Ocular Therapeutix Inc (OCUL) has a market capitalisation of $ 1,256 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Ocular Therapeutix Inc (OCUL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ocular Therapeutix Inc (OCUL) and enter the required number of quantities and click on buy to purchase the shares of Ocular Therapeutix Inc (OCUL).
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Address: 15 Crosby Drive, Bedford, MA, United States, 01730
The CEO & director of Mr. Antony Mattessich. is Ocular Therapeutix Inc (OCUL), and CFO & Sr. VP is Mr. Antony Mattessich.
There is no promoter pledging in Ocular Therapeutix Inc (OCUL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Ocular Therapeutix Inc. (OCUL) | Ratios |
|---|---|
|
Return on equity(%)
|
-95.21
|
|
Operating margin(%)
|
-282.36
|
|
Net Margin(%)
|
-303.67
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ocular Therapeutix Inc (OCUL) was $0 Mln.
$0.27
(
